MADRIGAL PHARMACEUTICALS ($MDGL) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$3.32 per share, beating estimates of -$3.76 by $0.44. The company also reported revenue of $137,250,000, beating estimates of $116,039,433 by $21,210,567.
You can see Quiver Quantitative's $MDGL stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
MADRIGAL PHARMACEUTICALS Insider Trading Activity
MADRIGAL PHARMACEUTICALS insiders have traded $MDGL stock on the open market 54 times in the past 6 months. Of those trades, 0 have been purchases and 54 have been sales.
Here’s a breakdown of recent trading of $MDGL stock by insiders over the last 6 months:
- FRED B CRAVES has made 0 purchases and 17 sales selling 22,470 shares for an estimated $7,408,629.
- ROBERT E. WALTERMIRE (Senior VP, Chief Pharma Dev.) has made 0 purchases and 13 sales selling 15,885 shares for an estimated $5,390,968.
- RICHARD S LEVY has made 0 purchases and 5 sales selling 10,000 shares for an estimated $3,254,703.
- CAROLE HUNTSMAN (Chief Commercial Officer) has made 0 purchases and 11 sales selling 2,869 shares for an estimated $932,208.
- MARDI DIER (SVP and CFO) has made 0 purchases and 3 sales selling 2,219 shares for an estimated $720,592.
- REBECCA TAUB (Pres., R&D, and CMO) has made 0 purchases and 2 sales selling 2,337 shares for an estimated $679,025.
- WILLIAM JOHN SIBOLD (President and CEO) sold 1,584 shares for an estimated $531,020
- SHANNON T KELLEY (General Counsel) has made 0 purchases and 2 sales selling 692 shares for an estimated $214,759.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
MADRIGAL PHARMACEUTICALS Hedge Fund Activity
We have seen 158 institutional investors add shares of MADRIGAL PHARMACEUTICALS stock to their portfolio, and 112 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 371,771 shares (+inf%) to their portfolio in Q4 2024, for an estimated $114,717,377
- JANUS HENDERSON GROUP PLC removed 269,766 shares (-10.9%) from their portfolio in Q4 2024, for an estimated $83,241,694
- BRAIDWELL LP removed 183,818 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $56,720,720
- WOODLINE PARTNERS LP added 162,027 shares (+110.2%) to their portfolio in Q4 2024, for an estimated $49,996,671
- PRICE T ROWE ASSOCIATES INC /MD/ removed 144,933 shares (-19.8%) from their portfolio in Q4 2024, for an estimated $44,721,975
- UBS GROUP AG added 144,644 shares (+80.1%) to their portfolio in Q4 2024, for an estimated $44,632,799
- HOOD RIVER CAPITAL MANAGEMENT LLC added 127,839 shares (+inf%) to their portfolio in Q4 2024, for an estimated $39,447,280
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
MADRIGAL PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $MDGL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- H.C. Wainwright issued a "Buy" rating on 01/14/2025
To track analyst ratings and price targets for MADRIGAL PHARMACEUTICALS, check out Quiver Quantitative's $MDGL forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
